Loading...

Biotec Pharmacon

DB:B4V
Snowflake Description

Excellent balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
B4V
DB
NOK204M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Biotec Pharmacon ASA, together with its subsidiaries, develops, manufactures, and markets immune modulating beta-glucans and recombinant enzymes in Norway. The last earnings update was 12 days ago. More info.


Add to Portfolio Compare Print
B4V Share Price and Events
7 Day Returns
-2.3%
DB:B4V
-0.1%
DE Biotechs
1%
DE Market
1 Year Returns
-37.1%
DB:B4V
-7.4%
DE Biotechs
-5.6%
DE Market
B4V Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Biotec Pharmacon (B4V) -2.3% -0.7% -11.3% -37.1% -69% -80.4%
DE Biotechs -0.1% 6% -6.7% -7.4% 53.2% 11.6%
DE Market 1% 6.1% 8.4% -5.6% 10.9% 13.8%
1 Year Return vs Industry and Market
  • B4V underperformed the Biotechs industry which returned -7.4% over the past year.
  • B4V underperformed the Market in Germany which returned -5.6% over the past year.
Price Volatility
B4V
Industry
5yr Volatility vs Market

B4V Value

 Is Biotec Pharmacon undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Biotec Pharmacon to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Biotec Pharmacon.

DB:B4V Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:B4V
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.453 (1 + (1- 23%) (0%))
1.303
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.3
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.303 * 5.96%)
8%

Discounted Cash Flow Calculation for DB:B4V using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Biotec Pharmacon is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:B4V DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (NOK, Millions) Source Present Value
Discounted (@ 8%)
2019 0.00 Analyst x1 0.00
2020 5.00 Analyst x1 4.29
2021 28.00 Analyst x1 22.23
2022 50.08 Est @ 78.86% 36.82
2023 77.76 Est @ 55.27% 52.93
2024 107.90 Est @ 38.76% 68.01
2025 137.25 Est @ 27.2% 80.10
2026 163.48 Est @ 19.11% 88.34
2027 185.46 Est @ 13.44% 92.80
2028 203.04 Est @ 9.48% 94.08
Present value of next 10 years cash flows NOK539.60
DB:B4V DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= NOK203.04 × (1 + 0.23%) ÷ (8% – 0.23%)
NOK2,619.54
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= NOK2,619.54 ÷ (1 + 8%)10
NOK1,213.75
DB:B4V Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= NOK539.60 + NOK1,213.75
NOK1,753.35
Equity Value per Share
(NOK)
= Total value / Shares Outstanding
= NOK1,753.35 / 48.33
NOK36.28
DB:B4V Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:B4V represents 0.09858x of OB:BIOTEC
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.09858x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (NOK) x Listing Adjustment Factor
= NOK 36.28 x 0.09858
€3.58
Value per share (EUR) From above. €3.58
Current discount Discount to share price of €0.42
= -1 x (€0.42 - €3.58) / €3.58
88.4%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Biotec Pharmacon is available for.
Intrinsic value
>50%
Share price is €0.42 vs Future cash flow value of €3.58
Current Discount Checks
For Biotec Pharmacon to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Biotec Pharmacon's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Biotec Pharmacon's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Biotec Pharmacon's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Biotec Pharmacon's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:B4V PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in NOK NOK-0.30
OB:BIOTEC Share Price ** OB (2019-04-24) in NOK NOK4.22
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.73x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.72x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Biotec Pharmacon.

DB:B4V PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OB:BIOTEC Share Price ÷ EPS (both in NOK)

= 4.22 ÷ -0.30

-13.92x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Biotec Pharmacon is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Biotec Pharmacon is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Biotec Pharmacon's expected growth come at a high price?
Raw Data
DB:B4V PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -13.92x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
102.6%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Biotec Pharmacon, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Biotec Pharmacon's assets?
Raw Data
DB:B4V PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in NOK NOK1.10
OB:BIOTEC Share Price * OB (2019-04-24) in NOK NOK4.22
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.72x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:B4V PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OB:BIOTEC Share Price ÷ Book Value per Share (both in NOK)

= 4.22 ÷ 1.10

3.85x

* Primary Listing of Biotec Pharmacon.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Biotec Pharmacon is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Biotec Pharmacon's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Biotec Pharmacon has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

B4V Future Performance

 How is Biotec Pharmacon expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
102.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Biotec Pharmacon expected to grow at an attractive rate?
  • Biotec Pharmacon's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Biotec Pharmacon's earnings growth is expected to exceed the Germany market average.
  • Biotec Pharmacon's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:B4V Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:B4V Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 102.6%
DB:B4V Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 20%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:B4V Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in NOK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:B4V Future Estimates Data
Date (Data in NOK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 130 30 30 1
2020-12-31 101 6 7 1
2019-12-31 80 1 -5 1
DB:B4V Past Financials Data
Date (Data in NOK Millions) Revenue Cash Flow Net Income *
2018-12-31 73 -18 -14
2018-09-30 70 -24 -20
2018-06-30 63 -22 -27
2018-03-31 69 -23 -27
2017-12-31 73 -22 -25
2017-09-30 74 -23 -26
2017-06-30 80 -22 -24
2017-03-31 79 -18 -21
2016-12-31 79 -19 -20
2016-09-30 78 -14 -20
2016-06-30 72 -13 -19
2016-03-31 66 -14 -18

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Biotec Pharmacon's earnings are expected to grow significantly at over 20% yearly.
  • Biotec Pharmacon's revenue is expected to grow by 20% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:B4V Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Biotec Pharmacon Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:B4V Future Estimates Data
Date (Data in NOK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 0.62 0.62 0.62 1.00
2020-12-31 0.14 0.14 0.14 1.00
2019-12-31 -0.11 -0.11 -0.11 1.00
DB:B4V Past Financials Data
Date (Data in NOK Millions) EPS *
2018-12-31 -0.30
2018-09-30 -0.42
2018-06-30 -0.58
2018-03-31 -0.62
2017-12-31 -0.57
2017-09-30 -0.57
2017-06-30 -0.55
2017-03-31 -0.47
2016-12-31 -0.47
2016-09-30 -0.47
2016-06-30 -0.42
2016-03-31 -0.42

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Biotec Pharmacon is expected to make outstanding use of shareholders’ funds in the future (Return on Equity greater than 40%).
X
Future performance checks
We assess Biotec Pharmacon's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Biotec Pharmacon has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

B4V Past Performance

  How has Biotec Pharmacon performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Biotec Pharmacon's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Biotec Pharmacon does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Biotec Pharmacon's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Biotec Pharmacon's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Biotec Pharmacon's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Biotec Pharmacon Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:B4V Past Revenue, Cash Flow and Net Income Data
Date (Data in NOK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 72.82 -13.99 45.31
2018-09-30 70.21 -19.69 57.17
2018-06-30 63.39 -26.95 58.93
2018-03-31 68.98 -26.89 59.96
2017-12-31 72.76 -24.94 51.97
2017-09-30 73.83 -25.52 58.93
2017-06-30 80.06 -23.79 58.40
2017-03-31 79.21 -21.16 57.48
2016-12-31 78.62 -20.48 56.89
2016-09-30 77.91 -20.21 52.98
2016-06-30 71.82 -18.72 50.82
2016-03-31 66.33 -17.94 49.32
2015-12-31 59.46 -17.34 46.94
2015-09-30 55.12 -15.00 42.06
2015-06-30 48.30 -16.49 40.89
2015-03-31 46.11 -17.65 39.45
2014-12-31 37.89 -21.99 37.95
2014-09-30 34.29 -22.88 38.25
2014-06-30 31.05 -21.45 37.24
2014-03-31 26.32 -23.89 37.43
2013-12-31 28.10 -22.89 37.51
2013-09-30 28.55 -23.11 33.32
2013-06-30 26.18 -25.17 33.33
2013-03-31 26.14 -26.13 33.60
2012-12-31 27.20 -24.32 33.40
2012-09-30 23.33 -24.06 35.58
2012-06-30 24.30 -22.59 35.12

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Biotec Pharmacon has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Biotec Pharmacon has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Biotec Pharmacon improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Biotec Pharmacon's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Biotec Pharmacon has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

B4V Health

 How is Biotec Pharmacon's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Biotec Pharmacon's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Biotec Pharmacon is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Biotec Pharmacon's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Biotec Pharmacon's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Biotec Pharmacon has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Biotec Pharmacon Company Filings, last reported 3 months ago.

DB:B4V Past Debt and Equity Data
Date (Data in NOK Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 53.90 0.00 31.66
2018-09-30 55.64 0.00 28.15
2018-06-30 56.27 0.00 35.16
2018-03-31 38.68 0.00 19.97
2017-12-31 44.82 0.00 30.59
2017-09-30 52.32 0.00 33.13
2017-06-30 59.93 0.00 38.40
2017-03-31 64.15 0.00 46.49
2016-12-31 68.09 0.00 57.67
2016-09-30 76.01 0.00 61.73
2016-06-30 81.66 0.00 64.70
2016-03-31 83.31 0.00 67.71
2015-12-31 86.75 0.00 78.34
2015-09-30 94.48 0.00 76.94
2015-06-30 98.83 0.00 78.27
2015-03-31 95.65 0.00 79.11
2014-12-31 98.87 0.00 88.28
2014-09-30 103.57 0.00 86.67
2014-06-30 108.53 0.00 88.99
2014-03-31 35.83 0.00 21.75
2013-12-31 42.52 0.00 33.66
2013-09-30 48.83 0.00 35.46
2013-06-30 53.61 0.00 42.28
2013-03-31 58.55 0.00 44.91
2012-12-31 21.91 0.00 9.38
2012-09-30 28.72 0.00 12.48
2012-06-30 35.56 0.00 19.71
  • Biotec Pharmacon has no debt.
  • Biotec Pharmacon has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Biotec Pharmacon has sufficient cash runway for 1.5 years based on current free cash flow.
  • Biotec Pharmacon has sufficient cash runway for 1.4 years if free cash flow continues to grow at historical rates of 19.9% each year.
X
Financial health checks
We assess Biotec Pharmacon's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Biotec Pharmacon has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

B4V Dividends

 What is Biotec Pharmacon's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Biotec Pharmacon dividends. Estimated to be 0% next year.
If you bought €2,000 of Biotec Pharmacon shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Biotec Pharmacon's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Biotec Pharmacon's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:B4V Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:B4V Future Dividends Estimate Data
Date (Data in NOK) Dividend per Share (annual) Avg. No. Analysts
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Biotec Pharmacon has not reported any payouts.
  • Unable to verify if Biotec Pharmacon's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Biotec Pharmacon's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Biotec Pharmacon has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Biotec Pharmacon's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Biotec Pharmacon's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Biotec Pharmacon afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Biotec Pharmacon has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

B4V Management

 What is the CEO of Biotec Pharmacon's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Christian Jørgensen
COMPENSATION NOK1,137,000
AGE 59
TENURE AS CEO 1.5 years
CEO Bio

Mr. Christian Jørgensen has been Chief Executive Officer at Biotec Pharmacon ASA since October 02, 2017. Mr. Jørgensen serves as General Manager of Western Europe at Baxter Healthcare, USA. He has extensive background from the global healthcare industry. Mr. Jørgensen served as Group Director of Coloplast A/S since May 2004 and its Executive Vice President from 2004 to 2006. Mr. Jørgensen served as Executive Vice President of Egmont from 1993 to 2001 and Chief Executive Officer of the mobile company 3 from 2002 to 2004. He served as President for Hill-Rom's European business. Mr. Jørgensen served as Director of Deadline Games A/S since 2007. He served as Member of Supervisory Board of RTX A/S until 2009. Mr. Jørgensen received MBA from INSEAD in 1992 and MSc. Econ. from the University of Copenhagen in 1985.

CEO Compensation
  • Insufficient data for Christian to compare compensation growth.
  • Christian's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Biotec Pharmacon management team in years:

4.4
Average Tenure
59
Average Age
  • The tenure for the Biotec Pharmacon management team is about average.
Management Team

Christian Jørgensen

TITLE
Chief Executive Officer
COMPENSATION
NOK1M
AGE
59
TENURE
1.5 yrs

Børge Sørvoll

TITLE
Chief Financial Officer
COMPENSATION
NOK1M
AGE
43
TENURE
4.5 yrs

Rolf Engstad

TITLE
Chief Scientific Officer of Biotec BetaGlucans AS
COMPENSATION
NOK2M
AGE
59
TENURE
12.6 yrs

Jethro Holter

TITLE
Managing Director of ArcticZymes AS
COMPENSATION
NOK2M
AGE
46
TENURE
4.3 yrs

Svein Lien

TITLE
Consultant
COMPENSATION
NOK4M
AGE
64
TENURE
1.5 yrs

Alexander Bjorna

TITLE
Director of IP & Business Development
TENURE
14.6 yrs
Board of Directors Tenure

Average tenure and age of the Biotec Pharmacon board of directors in years:

1.9
Average Tenure
59
Average Age
  • The average tenure for the Biotec Pharmacon board of directors is less than 3 years, this suggests a new board.
Board of Directors

Marie Roskrow

TITLE
Chairperson
TENURE
0.9 yrs

Inger Rydin

TITLE
Director
COMPENSATION
NOK200K
AGE
61
TENURE
4.9 yrs

Martin Hunt

TITLE
Director
COMPENSATION
NOK105K
AGE
59
TENURE
1.9 yrs

Ingrid Skjæveland

TITLE
Representative Director
COMPENSATION
NOK45K
AGE
41
TENURE
1.9 yrs

Arne Reinemo

TITLE
Director
TENURE
0.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
14. Nov 18 Buy Rolf Engstad Individual 14. Nov 18 14. Nov 18 100,000 €0.44 €44,077
23. Oct 18 Buy Rolf Engstad Individual 22. Oct 18 22. Oct 18 20,000 €0.47 €9,340
17. Aug 18 Buy Rolf Engstad Individual 17. Aug 18 17. Aug 18 20,000 €0.52 €10,322
16. May 18 Buy Rolf Engstad Individual 16. May 18 16. May 18 20,000 €0.67 €13,391
14. May 18 Buy Stuart Devine Individual 14. May 18 14. May 18 16,099 €0.70 €11,263
14. May 18 Buy Børge Sørvoll Individual 14. May 18 14. May 18 8,000 €0.67 €5,380
14. May 18 Buy Christian Jørgensen Individual 14. May 18 14. May 18 15,000 €0.67 €10,102
X
Management checks
We assess Biotec Pharmacon's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Biotec Pharmacon has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

B4V News

Simply Wall St News

B4V Company Info

Description

Biotec Pharmacon ASA, together with its subsidiaries, develops, manufactures, and markets immune modulating beta-glucans and recombinant enzymes in Norway. It operates through Enzymes and Beta-Glucans segments. It offers Woulgan Gel, an active wound healing product containing soluble beta-glucan; and M-Gard, an immunomodulator that enhances body’s defense mechanisms against pathogens, such as bacteria, virus, fungus, etc. The company also develops and markets recombinant enzymes that are derived from cold-water marine species for use in life science research and in the molecular diagnostics sector. Biotec Pharmacon ASA was founded in 1990 and is headquartered in Tromsø, Norway.

Details
Name: Biotec Pharmacon ASA
B4V
Exchange: DB
Founded: 1990
NOK21,171,392
48,334,673
Website: http://www.biotec.no
Address: Biotec Pharmacon ASA
Sykehusveien 23,
PO Box 6463,
Tromsø,
9294,
Norway
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OB BIOTEC Ordinary Shares Oslo Bors NO NOK 04. Nov 2005
DB B4V Ordinary Shares Deutsche Boerse AG DE EUR 04. Nov 2005
LSE 0DRV Ordinary Shares London Stock Exchange GB NOK 04. Nov 2005
BATS-CHIXE BIOTEO Ordinary Shares BATS 'Chi-X Europe' GB NOK 04. Nov 2005
Number of employees
Current staff
Staff numbers
38
Biotec Pharmacon employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/24 21:01
End of day share price update: 2019/04/24 00:00
Last estimates confirmation: 2019/03/20
Last earnings filing: 2019/04/12
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.